Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 18/20 | 0.82 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.82 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.82 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.65 |
| ▸ | MTOR | P42345 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761617 | 0.91 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL3763961 | 0.89 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL3662525 | 0.88 | PIK3CD (0.80) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL3770642 | 0.88 | PIK3CD (0.79) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL29807776 | 0.88 | PIK3CD (0.74) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL28800823 | 0.88 | PIK3CD (0.74) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL3761597 | 0.86 | PIK3CD (0.85) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL13654285 | 0.85 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL3662741 | 0.84 | PIK3CD (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 | |
| SCHEMBL3662656 | 0.84 | PIK3CG (0.77) | PIK3CDPIK3CGPIK3CAPIK3CBPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109721531-B | Novel liposome kinase inhibitor | 中国科学院合肥物质科学研究院 | 2022-07-29 | — | — | CN | disclosed |
| WO-2020147097-A1 | NOVEL LIPOSOME KINASE INHIBITOR | 中国科学院合肥物质科学研究院 | 2020-07-23 | — | — | WO | disclosed |
| WO-2020147097-A1 | NOVEL LIPOSOME KINASE INHIBITOR | 中国科学院合肥物质科学研究院 | 2020-07-23 | — | — | WO | disclosed |
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311736-A1 | PYRIDOSULFONAMIDE DERIVATIVES AS P13 KINASE INHIBITORS | PIKFYVE, JAK3, PI4KA | PIK3CD 18/4885PIK3CG 27/4885PIK3CA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.